3C-FE

3C-FE
Clinical data
Other names4-(2-Fluoroethoxy)-3,5-dimethoxyamphetamine; 3C-FEM; 3C-Fluoroescaline
Routes of
administration		Unknown[1][2][3]
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown[1][2][3]
Identifiers
  • 1-[4-(2-fluoroethoxy)-3,5-dimethoxyphenyl]propan-2-amine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC13H20FNO3
Molar mass257.305 g·mol−1
3D model (JSmol)
  • CC(CC1=CC(=C(C(=C1)OC)OCCF)OC)N
  • InChI=1S/C13H20FNO3/c1-9(15)6-10-7-11(16-2)13(18-5-4-14)12(8-10)17-3/h7-9H,4-6,15H2,1-3H3
  • Key:BILSAOCOBOYWEO-UHFFFAOYSA-N

3C-FE, also known as 4-(2-fluoroethoxy)-3,5-dimethoxyamphetamine or as 3C-fluoroescaline, is a serotonin receptor modulator of the phenethylamine, amphetamine, and 3C families.[1][4][5][3][2] It is the amphetamine (α-methyl) derivative of the psychedelic drug fluoroescaline (FE).[1][3][2]

According to Daniel Trachsel in his book Phenethylamine: von der Struktur zur Funktion and other publications, 3C-FE is inactive at doses of up to 24 mg orally, but has not been sufficiently investigated.[1][2] Hence, its properties and effects in humans remain unknown.[1][2][3]

The drug shows weak affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 5,987–12,000 nM and 8,400–>10,000 nM, respectively).[3][1][2] It is an agonist of the serotonin 5-HT2A and 5-HT2B receptors (EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) = 120 nM (102%) and 800 nM (29%), respectively).[2]

The chemical synthesis of 3C-FE has been described.[5]

3C-FE was first described in the scientific literature by Daniel Trachsel in 2002.[5][1][3]

See also

References

  1. ^ a b c d e f g h Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  2. ^ a b c d e f g h Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2021). "Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines". Frontiers in Pharmacology. 12 794254. doi:10.3389/fphar.2021.794254. PMC 8865417. PMID 35222010.
  3. ^ a b c d e f g Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819.
  4. ^ Shulgin A, Manning T, Daley PF (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. ISBN 978-0-9630096-3-0.
  5. ^ a b c Trachsel D (2002). "Synthese von neuen (Phenylalkyl)aminen zur Untersuchung von Struktur-Aktivitätsbeziehungen, Mitteilung 1, Mescalin Derivate" [Synthesis of new (phenylalkyl)amines for the investigation of structure-activity relationships, Communication 1, Mescaline derivatives]. Helvetica Chimica Acta. 85 (9): 3019–3026. doi:10.1002/1522-2675(200209)85:9<3019::AID-HLCA3019>3.0.CO;2-4.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.